S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
UK train strikes and energy hikes add to a week of turmoil
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Russia blindfolds, detains Ukraine nuclear plant chief
Ruptured oil pipeline off California approved for repairs
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
UK train strikes and energy hikes add to a week of turmoil
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Russia blindfolds, detains Ukraine nuclear plant chief
Ruptured oil pipeline off California approved for repairs
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
UK train strikes and energy hikes add to a week of turmoil
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Russia blindfolds, detains Ukraine nuclear plant chief
Ruptured oil pipeline off California approved for repairs
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
UK train strikes and energy hikes add to a week of turmoil
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Russia blindfolds, detains Ukraine nuclear plant chief
Ruptured oil pipeline off California approved for repairs
NASDAQ:RNA

Avidity Biosciences - RNA Stock Forecast, Price & News

$16.33
-0.39 (-2.33%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$16.25
$17.80
50-Day Range
$15.62
$23.43
52-Week Range
$10.89
$29.25
Volume
642,113 shs
Average Volume
564,859 shs
Market Capitalization
$851.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.60

Avidity Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.20 Rating Score
Upside/​Downside
148.6% Upside
$40.60 Price Target
Short Interest
Bearish
10.17% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.03mentions of Avidity Biosciences in the last 14 days
Based on 21 Articles This Week
Insider Trading
Selling Shares
$2.04 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.53) to ($3.78) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.48 out of 5 stars

Medical Sector

1035th out of 1,095 stocks

Pharmaceutical Preparations Industry

511th out of 547 stocks

RNA stock logo

About Avidity Biosciences (NASDAQ:RNA) Stock

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Receive RNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RNA Stock News Headlines

Avidity Biosciences (NASDAQ:RNA) Price Target Cut to $35.00
Avidity Biosciences (NASDAQ:RNA) Shares Gap Down on Analyst Downgrade
What 4 Analyst Ratings Have To Say About Avidity Biosciences
Avidity Biosciences, Inc. (RNA)
See More Headlines
Receive RNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RNA Company Calendar

Last Earnings
8/09/2022
Today
10/02/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RNA
Fax
N/A
Employees
125
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$40.60
High Stock Price Forecast
$59.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+148.6%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

Net Income
$-118,010,000.00
Net Margins
-1,849.49%
Pretax Margin
-1,849.49%

Debt

Sales & Book Value

Annual Sales
$9.33 million
Book Value
$8.13 per share

Miscellaneous

Free Float
48,687,000
Market Cap
$851.28 million
Optionable
Not Optionable
Beta
0.88

Key Executives

  • Dr. Troy Edward Wilson J.D. (Age 53)
    Ph.D., Co-Founder & Chairman
    Comp: $65k
  • Ms. Sarah Boyce (Age 50)
    Pres, CEO & Director
    Comp: $1M
  • Mr. Michael F. MacLean (Age 56)
    Chief Financial Officer
    Comp: $650.38k
  • Dr. W. Michael Flanagan Ph.D. (Age 60)
    Chief Technical Officer
    Comp: $1M
  • Dr. Arthur A. Levin Ph.D. (Age 68)
    Chief Scientific Officer
    Comp: $662.86k
  • Prof. Mark E. Davis
    Scientific Founder, Member of Scientific Advisory Board and Member of Board of Mang.s
  • Dr. Frank McCormick Ph.D. (Age 72)
    Scientific Founder & Member of Scientific Advisory Board
  • Ms. Kathleen Gallagher
    Sr. VP of Corp. Communications & Investor Relations
  • Dr. John W. Wallen III (Age 64)
    VP of Intellectual Property, Gen. Counsel & Sec.
  • Ms. Teresa McCarthy
    Chief HR Officer













RNA Stock - Frequently Asked Questions

Should I buy or sell Avidity Biosciences stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RNA shares.
View RNA analyst ratings
or view top-rated stocks.

What is Avidity Biosciences' stock price forecast for 2022?

5 Wall Street analysts have issued 1 year price targets for Avidity Biosciences' stock. Their RNA share price forecasts range from $27.00 to $59.00. On average, they expect the company's stock price to reach $40.60 in the next year. This suggests a possible upside of 148.6% from the stock's current price.
View analysts price targets for RNA
or view top-rated stocks among Wall Street analysts.

How have RNA shares performed in 2022?

Avidity Biosciences' stock was trading at $23.77 at the start of the year. Since then, RNA shares have decreased by 31.3% and is now trading at $16.33.
View the best growth stocks for 2022 here
.

When is Avidity Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our RNA earnings forecast
.

How were Avidity Biosciences' earnings last quarter?

Avidity Biosciences, Inc. (NASDAQ:RNA) announced its quarterly earnings results on Tuesday, August, 9th. The biotechnology company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.74) by $0.18. The biotechnology company had revenue of $2.18 million for the quarter, compared to analyst estimates of $2.29 million. Avidity Biosciences had a negative net margin of 1,849.49% and a negative trailing twelve-month return on equity of 38.72%.

What other stocks do shareholders of Avidity Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), iBio (IBIO), Intel (INTC), Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT).

When did Avidity Biosciences IPO?

(RNA) raised $150 million in an initial public offering on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO.

What is Avidity Biosciences' stock symbol?

Avidity Biosciences trades on the NASDAQ under the ticker symbol "RNA."

How do I buy shares of Avidity Biosciences?

Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avidity Biosciences' stock price today?

One share of RNA stock can currently be purchased for approximately $16.33.

How much money does Avidity Biosciences make?

Avidity Biosciences (NASDAQ:RNA) has a market capitalization of $851.28 million and generates $9.33 million in revenue each year. The biotechnology company earns $-118,010,000.00 in net income (profit) each year or ($3.13) on an earnings per share basis.

How many employees does Avidity Biosciences have?

The company employs 125 workers across the globe.

How can I contact Avidity Biosciences?

Avidity Biosciences' mailing address is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. The official website for the company is www.aviditybiosciences.com. The biotechnology company can be reached via phone at 858-401-7900 or via email at amy@juniper-point.com.

This page (NASDAQ:RNA) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.